
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc demonstrates a positive outlook due to its strategic dual-track approach in developing therapies for supportive oncology and metabolic diseases, which may enhance incremental value through its joint venture programs. The company reported that over 65% of participants in its clinical evaluations experienced reductions in pain and pruritus, indicating significant symptom improvement and validating the potential efficacy of its treatments. Additionally, Hoth's second quarter 2025 results reflect effective expense management while concurrently advancing its lead asset, HT-001, into an expanded development pathway, showcasing its operational discipline and growth potential in the biopharmaceutical sector.
Bears say
Hoth Therapeutics Inc reported no revenues for the second quarter of 2025, consistent with expectations, while total operating expenses decreased to $2.2 million from $3.4 million in the previous quarter. The company incurred a net loss of $2.2 million, translating to $(0.17) per share for the quarter, reflecting ongoing financial challenges. This continued absence of revenue generation, coupled with significant operating losses, raises concerns about the company's financial viability and the potential for future growth.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares